Srivastava P K
Department of Biological Sciences, Fordham University, Bronx, NY 10458, USA.
Semin Immunol. 1996 Oct;8(5):295-302. doi: 10.1006/smim.1996.0038.
A majority of CTL-recognized antigens of human melanomas have turned out to be unmutated differentiation antigens expressed on melanomas and melanocytes alike. Additional, relatively cancer-specific antigens which are expressed on a significant proportion of melanomas, but not on most normal tissues, have also been shown to be recognized by CTLs. Finally, CTLs have been shown to detect mutated oncoproteins which are expressed in a wide spectrum of cancers but not in normal tissues. These observations have given rise to a view that human cancers share a number of antigens, which can form the basis for their immunotherapy. In contrast, cancer antigens of mice and rats (which are detected by tumor rejection assays in vivo, rather than CTLs generated in vitro) have been observed, generally, to be individually distinct, i.e. unique for each individual cancer. No convincing examples of shared cancer antigens exist in animal models of cancer. This dichotomy between the nature of cancer antigens of humans ('shared'), and of rodents ('unique') is addressed, and hopefully, resolved in this article.
事实证明,人类黑色素瘤的大多数细胞毒性T淋巴细胞(CTL)识别抗原都是未发生突变的分化抗原,在黑色素瘤和黑素细胞上均有表达。此外,在相当一部分黑色素瘤上表达,但在大多数正常组织上不表达的相对癌症特异性抗原,也已被证明能被CTL识别。最后,CTL已被证明能检测到在多种癌症中表达但在正常组织中不表达的突变癌蛋白。这些观察结果引发了一种观点,即人类癌症共享多种抗原,这可为其免疫治疗奠定基础。相比之下,小鼠和大鼠的癌症抗原(通过体内肿瘤排斥试验检测,而非体外产生的CTL)通常被观察到是个体独特的,即每种个体癌症都有其独特性。在癌症动物模型中不存在令人信服的共享癌症抗原的例子。本文探讨并有望解决人类癌症抗原(“共享”)与啮齿动物癌症抗原(“独特”)性质之间的这种二分法。